Alligator Bioscience AB (FRA:7AL0) Short Percentage of Float


FRA:7AL0 Alligator Bioscience AB FRA:7AL0
39 GF Score
Price €0.00
! 7 Warning Signs
View Full Analysis

What is Alligator Bioscience AB Short Percentage of Float?

Short Percentage of Float is the percentage of shares shorted compared to the float.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

FRA:7AL0 vs VRTX, REGN, ALNY: Short Percentage of Float Comparison

For the Biotechnology subindustry, Alligator Bioscience AB's Short Percentage of Float, along with its competitors' market caps and Short Percentage of Float data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Alligator Bioscience AB Short Percentage of Float vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Alligator Bioscience AB's Short Percentage of Float distribution charts can be found below:

* The bar in red indicates where Alligator Bioscience AB's Short Percentage of Float falls into.


FRA:7AL0
39GF Score
Alligator Bioscience AB FRA:7AL0
Short Percentage of Float is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Alligator Bioscience AB Business Description

Other Exchanges ATORX:Sweden0RK9:UK
Address Scheeletorget 1, Medicon Village, Lund, SWE, 223 81
Alligator Bioscience AB is a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs focused on the CD40 receptor. The company's main drug candidate, mitazalimab, is currently under development as a therapy for metastatic pancreatic cancer patients. Its development pipeline also comprises: ATOR-4066, a bispecific antibody targeting CD40, as well as CEACAM5 (carcinoembryonic antigen 5), a protein found in certain tumors; and certain externally developed programs like HLX22 and ALG.APV-527. Geographically, the company generates maximum revenue from Belgium (mainly through out-licensing), and also has its presence in Sweden and Finland.
39GF Score

Get the complete analysis for FRA:7AL0

Short Percentage of Float is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.00
Price